Forte Biosciences Names New Director and CMO
Ticker: FBRX · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1419041
Sentiment: neutral
Topics: leadership-change, appointment, director
TL;DR
Forte Bio brings in Dr. Roth as new CMO & Director, effective Sept 17.
AI Summary
Forte Biosciences, Inc. announced on September 17, 2024, the departure of Director Dr. David S. Scholl and the election of Dr. Jonathan S. Roth as a new director. The company also appointed Dr. Roth as Chief Medical Officer and announced a new compensatory arrangement for him, effective September 17, 2024.
Why It Matters
The appointment of a new Chief Medical Officer and director signals a potential shift in the company's leadership and strategic direction, particularly in its medical and scientific endeavors.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- Dr. David S. Scholl (person) — Departing Director
- Dr. Jonathan S. Roth (person) — Newly Elected Director and Chief Medical Officer
- September 17, 2024 (date) — Effective date of changes
FAQ
Who has departed from the board of directors at Forte Biosciences, Inc.?
Dr. David S. Scholl has departed from the board of directors.
Who has been appointed as a new director and Chief Medical Officer?
Dr. Jonathan S. Roth has been appointed as a new director and Chief Medical Officer.
When were these changes effective?
The changes were effective as of September 17, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 3060 Pegasus Park Dr., Building 6, Dallas, Texas 75247.
What was the former name of Forte Biosciences, Inc.?
The former name of Forte Biosciences, Inc. was Tocagen Inc.
Filing Stats: 1,973 words · 8 min read · ~7 pages · Grade level 10 · Accepted 2024-09-20 16:50:27
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
- $42,500 — Mr. Vincent will be entitled to receive $42,500 per year for service as a member of the
- $24,000 — as a member of the Board and a total of $24,000 per year for service as a member of and
- $5,000 — or service as a member of the Board and $5,000 per year for service as a member of the
- $1,500,000.00 — ake a payment to Plaintiff's counsel of $1,500,000.00. The Dismissal is with prejudice as t
Filing Documents
- d844019d8k.htm (8-K) — 38KB
- 0001193125-24-222962.txt ( ) — 161KB
- fbrx-20240917.xsd (EX-101.SCH) — 3KB
- fbrx-20240917_lab.xml (EX-101.LAB) — 18KB
- fbrx-20240917_pre.xml (EX-101.PRE) — 11KB
- d844019d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: September 20, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer